Jupiter Neurosciences
JUNS
2 hedge funds and large institutions have $66.3K invested in Jupiter Neurosciences in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0.01% less ownership
Funds ownership: 0.02% → 0% (-0.01%)
71% less capital invested
Capital invested by funds: $231K → $66.3K (-$164K)
71% less funds holding
Funds holding: 7 → 2 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$76.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$62.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$41.7K |
| 4 |
Two Sigma Investments
New York
|
-$13.3K |
| 5 |
HF
HRT Financial
New York
|
-$9K |
JUNS Hedge Fund Activity: Q2 2025 in Review
2 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Jupiter Neurosciences (JUNS) for Q2 2025, worth a combined $66.3K — down 71% from $231K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of JUNS and 0 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Citigroup, cutting an estimated $76.9K.
- 2 institutional investors held Jupiter Neurosciences (JUNS) as of Q2 2025, down from 7 in Q1 2025.
- Funds reported $66.3K of Jupiter Neurosciences stock for Q2 2025, down 71% quarter-over-quarter.
- 0 funds opened new Jupiter Neurosciences positions in Q2 2025 and 5 closed out, a net change of -5 holders.
- The largest Jupiter Neurosciences seller in Q2 2025 was Citigroup, an estimated $76.9K sold.
Based on aggregated 13F filings for Q2 2025.